作者
A. V. Shulga,Vadzim I. Talochka,С. А. Маскевич,Sokolova Za,А. А. Кныш,Igor R. Nabiev
摘要
Human epidermal growth factor receptor 2 (HER2, HER2/neu) is one of the most extensively studied and, at the same time, rapidly evolving molecular targets in modern oncology. Whereas the clinical significance of HER2 was initially associated almost exclusively with receptor overexpression and gene amplification in breast cancer, the spectrum of HER2-associated malignancies has now expanded substantially, and the very concept of HER2 positivity is undergoing a fundamental transformation. This review systematizes current knowledge of the biological role of HER2, the patterns of its overexpression, amplification, and activating mutations across solid tumors, as well as diagnostic approaches and opportunities for HER2-targeted therapy. Particular attention is given to breast, gastric and gastroesophageal junction, colorectal, and non-small-cell lung cancers, as well as tumors of the urinary bladder, biliary tract, salivary glands, and ovaries. HER2 protein overexpression, ERBB2 amplification, and activating mutations represent biologically and clinically distinct alterations and should not be indiscriminately grouped under the umbrella term “HER2-positive tumor”. The evolution of anti-HER2 therapy is traced from monoclonal antibodies and tyrosine kinase inhibitors to antibody – drug conjugates and bispecific antibodies. The emergence of highly effective antibody – drug conjugates, particularly trastuzumab deruxtecan, has extended the therapeutically relevant HER2 spectrum beyond classical overexpression, giving rise to the concepts of HER2-low and HER2-ultralow disease and facilitating the development of tumor-agnostic therapeutic approaches. The limitations of current methods for determining HER2 status are critically assessed, highlighting that direct extrapolation of diagnostic criteria established for breast cancer to other tumor types is not always methodologically justified. Emerging strategies to improve the sensitivity and objectivity of detecting low-level HER2 expression, including quantum dot-based fluorescent biosensors, are also considered. Collectively, current evidence supports a transition from binary HER2 assessment toward a multilevel model integrating receptor expression, ERBB2 amplification and mutational status, tumor type, and the therapeutic platform employed. This framework may enable more precise patient stratification and further expand the scope of personalized anticancer therapy.